
Sign up to save your podcasts
Or


This week, we talk about one of the big contributors to heart failure: inflammation. Heart failure affects millions and comes in two main types: HFrEF (weakened pumping) and HFpEF (thickened, stiff walls). While conditions like high blood pressure and diabetes contribute, chronic inflammation—driven in part by Interleukin 6 (IL-6)—plays a major role. IL-6 causes muscle damage, fibrosis, and worsens other diseases. Researchers are developing monoclonal antibodies to regulate IL-6, offering a potential breakthrough technology in reducing inflammation and improving heart health.
Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube
For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com
Thank you for listening!
References:
Martin, S. S., et al. (2024). 2024 heart disease and stroke statistics..., 149(8), e347-e913. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209
Oktay, A. A., et al. (2013). The emerging epidemic of heart failure with preserved ejection fraction. Current heart failure reports, 10, 401-410. https://pmc.ncbi.nlm.nih.gov/articles/PMC3870014/
Centers for Disease Control. (15 May, 2024). About Heart Failure. U.S. Department of Health and Human Services. https://www.cdc.gov/heart-disease/about/heart-failure.html
Groenewegen, A., et al. (2020). Epidemiology of heart failure. European journal of heart failure, 22(8), 1342-1356. https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1858
Redfield, M. M. (2016). Heart failure with preserved ejection fraction. New England Journal of Medicine, 375(19), 1868-1877. https://www.nejm.org/doi/full/10.1056/NEJMcp1511175
Chia, Y. C., et al. (2021). Interleukin 6 and development of heart failure with preserved ejection fraction in the general population. Journal of the American Heart Association, 10(11), e018549. https://www.ahajournals.org/doi/full/10.1161/JAHA.120.018549
Deswal, A., et al. (2001). Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation, 103(16), 2055-2059. https://www.ahajournals.org/doi/full/10.1161/01.CIR.103.16.2055
Murphy, S. P., et al. (2020). Inflammation in heart failure: JACC state-of-the-art review. Journal of the American College of Cardiology, 75(11), 1324-1340. https://www.jacc.org/doi/full/10.1016/j.jacc.2020.01.014
Fontes, J. A., et al. (2015). The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine, 74(1), 62-68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4677779/
Aber
Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube
For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! Podcast and MedEvidence.com
Thank you for listening!
By MedEvidence ArticlesThis week, we talk about one of the big contributors to heart failure: inflammation. Heart failure affects millions and comes in two main types: HFrEF (weakened pumping) and HFpEF (thickened, stiff walls). While conditions like high blood pressure and diabetes contribute, chronic inflammation—driven in part by Interleukin 6 (IL-6)—plays a major role. IL-6 causes muscle damage, fibrosis, and worsens other diseases. Researchers are developing monoclonal antibodies to regulate IL-6, offering a potential breakthrough technology in reducing inflammation and improving heart health.
Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube
For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! podcast. www.MedEvidence.com
Thank you for listening!
References:
Martin, S. S., et al. (2024). 2024 heart disease and stroke statistics..., 149(8), e347-e913. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209
Oktay, A. A., et al. (2013). The emerging epidemic of heart failure with preserved ejection fraction. Current heart failure reports, 10, 401-410. https://pmc.ncbi.nlm.nih.gov/articles/PMC3870014/
Centers for Disease Control. (15 May, 2024). About Heart Failure. U.S. Department of Health and Human Services. https://www.cdc.gov/heart-disease/about/heart-failure.html
Groenewegen, A., et al. (2020). Epidemiology of heart failure. European journal of heart failure, 22(8), 1342-1356. https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1858
Redfield, M. M. (2016). Heart failure with preserved ejection fraction. New England Journal of Medicine, 375(19), 1868-1877. https://www.nejm.org/doi/full/10.1056/NEJMcp1511175
Chia, Y. C., et al. (2021). Interleukin 6 and development of heart failure with preserved ejection fraction in the general population. Journal of the American Heart Association, 10(11), e018549. https://www.ahajournals.org/doi/full/10.1161/JAHA.120.018549
Deswal, A., et al. (2001). Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation, 103(16), 2055-2059. https://www.ahajournals.org/doi/full/10.1161/01.CIR.103.16.2055
Murphy, S. P., et al. (2020). Inflammation in heart failure: JACC state-of-the-art review. Journal of the American College of Cardiology, 75(11), 1324-1340. https://www.jacc.org/doi/full/10.1016/j.jacc.2020.01.014
Fontes, J. A., et al. (2015). The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine, 74(1), 62-68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4677779/
Aber
Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube
For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! Podcast and MedEvidence.com
Thank you for listening!